[{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Edesa Biotech","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Licensing Agreement","leadProduct":"NI-0101","moa":"Toll-like-4 receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Light Chain Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Light Chain Bioscience \/ Edesa Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Light Chain Bioscience \/ Edesa Biotech"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"CSHL","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Lonodelestat","moa":"Human neutrophil elastase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Undisclosed","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Santhera Pharmaceuticals \/ CSHL","highestDevelopmentStatusID":"1","companyTruncated":"Santhera Pharmaceuticals \/ CSHL"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Santhera will provide lonodelestat and intellectual support for the scientists at CSHL who will conduct the non-clinical research program.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 27, 2020

                          Lead Product(s) : Lonodelestat

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : CSHL

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The companies singed this exclusive worldwide license to develop and commercialize two Phase 2-ready biologic drug candidates for all therapeutic, prophylactic and diagnostic applications.

                          Product Name : NI-0101

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          April 20, 2020

                          Lead Product(s) : NI-0101

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Edesa Biotech

                          Deal Size : $372.0 million

                          Deal Type : Licensing Agreement

                          blank